Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248623 | 0.82 | — | — | |
| SCHEMBL838190 | 0.82 | — | — | |
| SCHEMBL6806645 | 0.80 | — | — | |
| SCHEMBL987906 | 0.80 | TSHR (0.65) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL15077030 | 0.78 | — | — | |
| SCHEMBL8775768 | 0.77 | TSHR (0.42) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Acetic Acid SCHEMBL11076307 | 0.75 | TSHR (0.58) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL16198017 | 0.75 | TSHR (0.58) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL1460735 | 0.75 | TSHR (0.58) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL3392585 | 0.74 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008722-A1 | NOVEL RIG-I LIGANDS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-3398956-B1 | NOVEL RIG-I LIGANDS AND METHODS FOR PRODUCING THEM | UNIV BONN RHEINISCHE FRIEDRICH WILHELMS (DE) | 2021-11-03 | — | — | EP | disclosed |
| US-11142763-B2 | RIG-I ligands and methods for producing them | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2021-10-12 | — | — | US | disclosed |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3199538-B1 | PURIFICATION OF TRIPHOSPHORYLATED OLIGONUCLEOTIDES USING CAPTURE TAGS AND MODIFIED TRIPHOSPHORYLATED OLIGONUCLEOTIDES AS ACTIVATORS OF RIG-1 HELICASE | UNIV BONN RHEINISCHE FRIEDRICH WILHELMS (DE) | 2020-05-27 | — | — | EP | disclosed |
| US-20190085328-A1 | IN VIVO SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | UNIVERSITY OF MASSACHUSETTS | 2019-03-21 | — | — | US | disclosed |
| EP-3398956-A1 | NOVEL RIG-I LIGANDS AND METHODS FOR PRODUCING THEM | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2018-11-07 | — | — | EP | disclosed |
| US-20180312841-A1 | NOVEL RIG-I LIGANDS AND METHODS FOR PRODUCING THEM | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2018-11-01 | — | — | US | disclosed |
| US-10087441-B2 | In vivo gene silencing by chemically modified and stable siRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2018-10-02 | — | — | US | disclosed |
| US-10072262-B2 | RIG-I ligands and methods for producing them | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2018-09-11 | — | — | US | disclosed |
| WO-2007092182-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20060069050-A1 | Methods and compositions for mediating gene silencing | UNIVERSITY OF MASSACHUSETTS (US) | 2006-03-30 | — | — | US | disclosed |
| US-20050273868-A1 | Methods and compositions for enhancing RISC activity in vitro and in vivo | UNIVERSITY OF MASSACHUSETTS (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005079532-A2 | METHODS AND COMPOSITIONS FOR ENHANCING RISC ACTIVITY IN VITRO AND IN VIVO | UNIVERSITY OF MASSACHUSETTS (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005079533-A2 | METHODS AND COMPOSITIONS FOR MEDIATING GENE SILENCING | UNIVERSITY OF MASSACHUSETTS (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1556402-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | University of Massachusetts (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050020521-A1 | Rna interference strands and antibody strands | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040152651-A1 | Regulation of transcription elongation factors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-05 | — | — | US | disclosed |
| WO-2004041838-A1 | REGULATION OF TRANSCRIPTION ELONGATION FACTORS | UNIVERSITY OF MASSACHUSETTS (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004029212-A2 | IN VIVO GENE SILENCING BY CHEMICALLY MODIFIED AND STABLE SIRNA | UNIVERSITY OF MASSACHUSETTS (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190085328-A1 | IN VIVO SILENCING BY CHEMICALLY MODIFIED AND STABLE siRNA | AGO2, SNRPE, NSUN2 | TSHR 3904/4885CHRM2 4685/4885CHRM4 4730/4885 |
| US-11142763-B2 | RIG-I ligands and methods for producing them | MAVS, EIF2AK2, ADAR | TSHR 1949/4885CHRM2 4646/4885CHRM4 3607/4885 |
| US-10072262-B2 | RIG-I ligands and methods for producing them | MAVS, EIF2AK2, ADAR | TSHR 1949/4885CHRM2 4646/4885CHRM4 3607/4885 |
| US-20050020521-A1 | Rna interference strands and antibody strands | AGO2, NSUN3, NSUN2 | TSHR 3338/4885CHRM2 4816/4885CHRM4 4805/4885 |
| US-11136578-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | TSHR 4016/4885CHRM2 4778/4885CHRM4 4818/4885 |
| US-10087441-B2 | In vivo gene silencing by chemically modified and stable siRNA | SNRPE, AGO2, NSUN2 | TSHR 4016/4885CHRM2 4778/4885CHRM4 4818/4885 |
| US-20180312841-A1 | NOVEL RIG-I LIGANDS AND METHODS FOR PRODUCING THEM | MAVS, EIF2AK2, DDX5 | TSHR 2469/4885CHRM2 4705/4885CHRM4 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.